GlassScriptPhysician profile
Payton Marcum Eberling
NPI 1548021298
$1,364.08
in general payments reported to CMS, 2019-2025
23 companies · $779 in 2025
The $779 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $585 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $220.28 | 2024-2025 | |
| Lilly USA, LLC | $202.23 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Vanda Pharmaceuticals INC. | $169.00 | 2024-2025 | Fanapt, Hetlioz |
| Pfizer INC. | $147.23 | 2025 | |
| Axsome Therapeutics, INC. | $98.96 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $51.33 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $49.47 | 2024-2025 | |
| Tactile Systems Technology INC | $43.16 | 2025 | Nimbl, Flexitouch Plus |
| Dynavax Technologies Corporation | $42.96 | 2024-2025 | Heplisav-B |
| Astellas Pharma US INC | $39.78 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $39.17 | 2024-2025 | |
| Novo Nordisk INC | $37.53 | 2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.19 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.50 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $24.86 | 2024 | Gvoke Hypopen |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $20.73 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $18.18 | 2024 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $17.22 | 2024 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $15.90 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $15.32 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $14.61 | 2025 | Airsupra |
| Amgen INC. | $14.32 | 2024 | Prolia, Evenity |
| Sumitomo Pharma America, INC. | $14.15 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payton Eberling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.